Cagrilintide UK Research Grade Peptide Peptides Lab UK Anti Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance Circulation: Heart Failure Another win for brain centric obesity treatment approaches. Adding cagrilintide (an amylin analog) to semaglutide (a GLP 1 analog) enhances weight loss. 17.1% weight loss over 20 wk at highest dose, with weight still Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity